Welcome to the e-CCO Library Archive!

Filter:
P290. Biological predictors of depression in IBD: Preliminary results of the ISA study
P290. CMV in IBD patients – does it matter?
Authors:

M. Thörn1, A. Rönnblom1, B.-M. Eriksson1, F. Rorsman1, P. Sangfelt1, A. Wanders2, K. Bondeson3, 1Uppsala University, Dept of Medical Sciences, Uppsala, Sweden, 2Uppsala University, Dept of Immunology, Genetics and Pathology, Uppsala, Sweden, 3Uppsala University, Dept of Medical Biochemistry and Microbiology, Uppsala, Sweden

P290. Infliximab drug levels in Crohn's disease responding to the treatment
P290

Impact of induction therapy with 3 doses of infliximab on deep remission in paediatric patients with active Crohn's Disease

Authors:

E. Szymanska*1, M. Dadalski2, S. Szymanska3, W. Grajkowska3, M. Pronicki3, J. Kierkus2

1Children’s Memorial Health Institute, Department of Pediatrics, Nutrition and Metabolic Disorders,, Warsaw, Poland, 2Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology and Feeding Disorders, Warsaw, Poland, 3Children’s Memorial Heath Institute, Department of Pathology, Warsaw, Poland

P291.

“IBD MOM”: report of a new concept in the treatment of IBD in pregnancy

Authors:

A. Shitrit1, S. Granovsky-Grisaru2, T. Adar1, B. Koslowsky1, B. Mazuz1, M. Shenwald1, E. Goldin1, 1Shaare Zedek Medical Center, Digestive diseases institute, Jerusalem, Israel, 2Shaare Zedek Medical Center, Department of obstetrics and gynecology, division of maternal fetal medicine, Jerusalem, Israel

P291. Clinical course of perianal fistulas in Crohn's disease: a retrospective study
Authors:

L. Alessandroni1, C. Papi2, L.G. Papparella3, M.C. Addarii1, A. Kohn1, 1San Camillo-Forlanini Hospital, Rome, Italy, 2San Filippo-Neri Hospital, Rome, Italy, 3Campus Bio-Medico, Rome, Italy

P291. Factors associated with premature death in inflammatory bowel disease
P291. Infliximab versus adalimumab in Crohn's disease patients in daily clinical practice. A prospective single center experience
P291

Association between Inflammatory Bowel Disease activity and therapeutic drug monitoring of azathioprine and infliximab comparing free and total antidrug antibody measurement

Authors:

M. Ward*1, 2, B. Warner2, N. Unsworth3, J. Sanderson2, Z. Arkir3, P. Irving2

1Alfred Hospital, Gastroenterology, Melbourne, Australia, 2Guy’s and St. Thomas Hospital, Gastroenterology, London, United Kingdom, 3Guy’s and St. Thomas Hospital, Reference Chemistry, Viapath, London, United Kingdom

P292.

Smart phones for inflammatory bowel disease

Authors:

L. Patience1, A. Watson2, 1Centre of Health Science, Research and Development, Inverness, United Kingdom, 2Raigmore Hospital/Centre of Healt Science, Colorectal Surgery/Research and Development, Inverness, United Kingdom

P292. Clinical characteristics of inflammatory bowel disease may influence the cancer risk when using immunomodulators: incident cases of cancer in a multicenter case-control study
Authors:

C. Petruzziello1, A. Armuzzi2, A. Kohn3, R. D'Incà4, C. Papi5, L. Spina6, L. Guidi2, M.L. Scribano3, S. Onali1, G. Condino1, E. Calabrese1, R. Monterubbianesi3, P. Alvisi7, W. Fries8, G. Riegler9, F. Castiglione10, G. Margagnoni5, G. Meucci11, F. Rogai12, F. Pallone1, L. Biancone1, 1Università Tor Vergata, Roma, Italy, 2Med Int/GI CIC Università Cattolica, Roma, Italy, 3AO S. Camillo Forlanini, Roma, Italy, 4Università Padova, Padova, Italy, 5UOC GE/Hep, AO S. Filippo Neri, Roma, Italy, 6Università S. Donato, Milano, Milano, Italy, 7Ospedale Maggiore, Bologna, Bologna, Italy, 8Università Messina, Messina, Italy, 9SUN Seconda Università di Napoli, Napoli, Italy, 10Università Federico II, Napoli, Napoli, Italy, 11Ospedale S. Giuseppe, Milano, Milano, Italy, 12AOU Careggi, Firenze, Firenze, Italy

P292. Comparison of ulcerative colitis surveillance strategies: An analysis of cost-effectiveness
P292. Endoscopic dilatation of ileocolonic Crohn's (CD) strictures
P292

Immunogenicity of 13-valent pneumococcal conjugated vaccine in pediatric patients with inflammatory bowel disease

Authors:

A. Banaszkiewicz*1, B. Targonska2, K. Kowalska-Duplaga3, K. Karolewska-Bochenek1, A. Sieczkowska4, A. Gawronska1, U. Grzybowska-Chlebowczyk5, E. Krzesiek6, I. Lazowska-Przeorek1, M. Kotowska1, E. Sienkiewicz1, J. Walkowiak2, H. Gregorek7, A. Radzikowski1, P. Albrecht1

1Medical University of Warsaw, Dept. of Pediatric Gastroenterology and Nutrition, Warsaw, Poland, 2Poznan University of Medical Sciences, Dept. of Pediatric Gastroenterology and Metabolic Diseases, Poznan, Poland, 3Jagiellonian University Medical College, Department of Pediatrics, Gastroenterology and Nutrition, Krakow, Poland, 4Medical University of Gdansk, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Gdansk, Poland, 5Medical University of Silesia, Department of Pediatrics, Gastroenterology Unit, Katowice, Poland, 6Wroclaw Medical University, Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw, Poland, 7The Children's Memorial Health Institute, Department of Microbiology and Clinical Immunology, Warsaw, Poland

P293.

eHealth: Individualisation of MMX mesalamine treatment and optimization of disease course via a self-managed web-based solution in active ulcerative colitis

Authors:

N. Pedersen1,2, J. Burisch3, L. Martinsen4, M. Bennedsen5, P. Thielsen6, S. Bell7, Z. Vegh3, A. Haaber8, D. Duricova9, T. Jess10, E. Langholz11, P. Munkholm3, 1Herlev University Hospital, Department of Gastroenterology, Copenhagen, Denmark, 2University, Gastroenterology, Copenhagen, Denmark, 3University of Copenhagen, Gastroenterology, Herlev, Denmark, 4Nykøbing Falster Hospital, Gastroenterology, Nykøbing Falster, Denmark, 5Frederikssund Hospital, Gastroenterology, Frederikssund, Denmark, 6Herlev University Hospital, Gastroenterology, Herlev, Denmark, 7University of Melbourne, Gastroenterology, Melbourne, Australia, 8Gentofte Hospital, Gastroenterology, Gentofte, Denmark, 9Charls University Hospital, IBD research centre ISCARE a.s., Herlev, Denmark, 10State Serum Institute, Epidemiology, Copenhagen, Denmark, 11Gentofte, Gastroenterology, Gentofte, Denmark

P293. Bone density and bone metabolism in patients with inflammatory bowel disease
Authors:

I.A. Pintilie, O. Nedelciuc, A.M. Blaj, C. Mihai, C. Cijevschi Prelipcean, .University of Medicine and Pharmacy Gr. T. Popa, Center of Gastroenterology and Hepatology “St. Spiridon” Hospital, Iasi, Romania

P293. Risk of malignancies in a single center cohort of IBD-patients treated with immunosuppressives and anti-TNF-antibodies
P293. Should I stop my azathioprine doctor?
P293

The sooner, the better: Early treatment of Crohn's Disease precludes a bad outcome

Authors:

Y. Gonzalez Lama*, C. Suarez Ferrer, G.P. Irene, M. Calvo Moya, V. Matallana Royo, M.I. Vera Mendoza, L. Abreu Garcia

Hospital Puerta De Hierro, Gastroenterology, Madrid, Spain

P294.

Yield of colon surveillance and clinical outcome after faecal diversion in patients with Crohn's disease

Authors:

D. van den Nieuwendijk1, C.I. Baeten2, J.C. Hardwick1, R.A. Veenendaal1, A.R. Vahrmeijer2, B.A. Bonsing2, A.E. van der Meulen-de Jong1, 1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Leiden University Medical Center, Surgery, Leiden, Netherlands